EUVIMEDEUVIMED entdecken
Open Access

IL-6–GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models

Marisa Carbonaro iD, Kehui Wang, Hui Huang, Davor Frleta, Aditi Patel iD, Alexander Pennington, Mathieu Desclaux, Sven Moller-Tank iD, Justin Grindley, Judith Altarejos, Jun Zhong, Greg Polites und 11 weitere

Science Advances · 2023

DOI: 10.1126/sciadv.adf4490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2023. Verfasst von Marisa Carbonaro und 22 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA. Hauptthemen laut MEDLINE: Interleukin-6, Fatty Liver. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Liver steatosis is an increasing health issue with few therapeutic options, partly because of a paucity of experimental models. In humanized liver rodent models, abnormal lipid accumulation in transplanted human hepatocytes occurs spontaneously. Here, we demonstrate that this abnormality is associated with compromised interleukin-6 (IL-6)–glycoprotein 130 (GP130) signaling in human hepatocytes because of incompatibility between host rodent IL-6 and human IL-6 receptor (IL-6R) on donor hepatocytes. Restoration of hepatic IL-6–GP130 signaling, through ectopic expression of rodent IL-6R, constitutive activation of GP130 in human hepatocytes, or humanization of an Il6 allele in recipient mice, substantially reduced hepatosteatosis. Notably, providing human Kupffer cells via hematopoietic stem cell engraftment in humanized liver mice also corrected the abnormality. Our observations suggest an important role of IL-6–GP130 pathway in regulating lipid accumulation in hepatocytes and not only provide a method to improve humanized liver models but also suggest therapeutic potential for manipulating GP130 signaling in human liver steatosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-6Fatty LiverHumansMiceAnimalsCytokine Receptor gp130Lipid DropletsHepatocytesGlycoproteinsLipids

Substanzen

Interleukin-6Cytokine Receptor gp130GlycoproteinsLipids

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals Inc., Tarrytown, NY, USA.
  • Pyxant Labs Inc., Salt Lake City, UT, USA.

ORCID-Profile: Marisa Carbonaro, Aditi Patel, Sven Moller-Tank, William Poueymirou, Christos Kyratsous, Brian Zambrowicz, Andrew Murphy, Lynn E Macdonald, Christopher Daly, Mark Sleeman, Gavin Thurston, Zhe Li

Zitieren

APA

Carbonaro, M., Wang, K., Huang, H., Frleta, D., Patel, A., Pennington, A., Desclaux, M., Moller-Tank, S., Grindley, J., Altarejos, J., Zhong, J., Polites, G., Poueymirou, W., Jaspers, S., Kyratsous, C., Zambrowicz, B., Murphy, A., Lin, J. C., Macdonald, L. E., …, & Li, Z. (2023). IL-6–GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models. Science Advances. https://doi.org/10.1126/sciadv.adf4490

Vancouver

Carbonaro M, Wang K, Huang H, Frleta D, Patel A, Pennington A, et al. IL-6–GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models. Science Advances. 2023. doi:10.1126/sciadv.adf4490

BibTeX
@article{Carbonaro2023,
  author = {Carbonaro, Marisa and Wang, Kehui and Huang, Hui and Frleta, Davor and Patel, Aditi and Pennington, Alexander and Desclaux, Mathieu and Moller-Tank, Sven and Grindley, Justin and Altarejos, Judith and Zhong, Jun and Polites, Greg and Poueymirou, William and Jaspers, Stephen and Kyratsous, Christos and Zambrowicz, Brian and Murphy, Andrew and Lin, John C and Macdonald, Lynn E and Daly, Christopher and Sleeman, Mark and Thurston, Gavin and Li, Zhe},
  title = {IL-6–GP130 signaling protects human hepatocytes against lipid droplet accumulation in humanized liver models},
  journal = {Science Advances},
  year = {2023},
  doi = {10.1126/sciadv.adf4490}
}
Kostenlos starten →